top of page
Latest news
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, AUSTRALIA, 15 May 2026 — Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide
May 153 min read
Rage Bio Becomes Atisama Therapeutics
Rebrand marks transition into clinical-stage development and expansion of preclinical programs into new inflammatory disease targets using SSO platform. MELBOURNE, AUSTRALIA, 15 May 2026 — Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing precision splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today announced its rebrand from Rage Bio to Atisama Therapeut
May 142 min read
Rage Bio secures AU$29 million in Series A funding. Appoints Siro Perez as Chief Executive Officer & Edwin Tucker as Chief Medical and Development Officer.
Melbourne, Australia – RAGE Biotech Pty Ltd (‘Rage Bio’), a company developing precision splice-switching oligonucleotide (SSO) therapeutics to fight chronic inflammatory disease, has raised $A29 million in its Series A funding round. Rage Bio has also announced two key executive appointments, naming Dr Siro Perez as Chief Executive Officer and Dr. Edwin Tucker as Chief Medical and Development Officer. The funding round was led by IP Group Australia and Hostplus, with continu
May 114 min read
bottom of page